RxDoctor Payments Data

Sayyadul Siddiqui, MD

Interventional Cardiology · Little Rock, ARNPI 1477635027

Payments from drug & device makers

$1,015in general payments, 2019–2025

Across 44 payments — averaging $23.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$195
  • Shockwave Medical, Inc$143
  • E.r. Squibb & Sons, L.L.C.$135
  • Abiomed$133
  • Novartis$115
  • Boston Scientific$51
  • plus $243 from 10 others

What the payments were for

  • Food & beverage$1,015100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,015 in reported general payments places this provider in the 0th percentile of 89 interventional cardiology providers in Arkansas.

See all interventional cardiology providers in Arkansas

Medicare billing

Part B allowed, 2024
$255,920
Medicare patients
1,196
Services billed
4,094

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban564$479,078
JardianceEmpagliflozin464$321,317
FarxigaDapagliflozin Propanediol259$188,226
EntrestoSacubitril/Valsartan128$113,601
XareltoRivaroxaban111$88,659
Repatha SureclickEvolocumab76$56,963
OzempicSemaglutide41$37,366
MultaqDronedarone Hcl24$28,276
Ranolazine ErRanolazine177$14,764
Metoprolol Succinate757$10,881
Bumetanide336$7,511
Rosuvastatin Calcium489$6,147
ClopidogrelClopidogrel Bisulfate525$5,465
Atorvastatin Calcium474$4,646
Potassium Chloride173$3,754

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$32$188,226259 claims
NovartisEntresto$115$113,601128 claims
Johnson & JohnsonXarelto$31$88,659111 claims
Sanofi-aventis U.S. LLCMultaq$16$28,27624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 0th percentile of 89 interventional cardiology providers in Arkansas.

Other interventional cardiology in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →